ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 735 USD | -2.77% |
|
+0.20% | +26.08% |
| May. 03 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
| May. 03 | News Highlights : Top Company News of the Day - Friday at 7 PM ET | DJ |
Financials (USD)
| Sales 2024 * | 42.76B | Sales 2025 * | 52.13B | Capitalization | 662B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.94B | Net income 2025 * | 16.29B | EV / Sales 2024 * | 15.9 x |
| Net Debt 2024 * | 19.98B | Net Debt 2025 * | 15.29B | EV / Sales 2025 * | 13 x |
| P/E ratio 2024 * |
54.7
x | P/E ratio 2025 * |
40
x | Employees | 43,000 |
| Yield 2024 * |
0.71% | Yield 2025 * |
0.82% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -2.77% | ||
| 1 week | +0.20% | ||
| Current month | -5.91% | ||
| 1 month | -4.31% | ||
| 3 months | +10.08% | ||
| 6 months | +29.44% | ||
| Current year | +26.08% |
1 week
729.61
795.50
1 month
718.30795.50
Current year
579.05800.78
1 year
419.80800.78
3 years
189.32800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 735 | -2.77% | 4,595,138 |
| 24-05-02 | 755.9 | -2.68% | 3,205,628 |
| 24-05-01 | 776.8 | -0.56% | 2,804,838 |
| 24-04-30 | 781.1 | +5.95% | 7,437,105 |
| 24-04-29 | 737.2 | +0.50% | 2,732,584 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
735
USD
Average target price
848.3
USD
Spread / Average Target
+15.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- LLY Stock
